

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/870,144	05/30/2001	Eva Sevick-Muraca	017575.0680	913,1	
5073	7590 11/04/2004		EXAMINER c.		
BAKER BOTTS L.L.P.			JUNG, WIL	JUNG, WILLIAM C	
2001 ROSS AVENUE SUITE 600		ART UNIT	PAPER NUMBER		
DALLAS, TX 75201-2980			3737		
			DATE MAILED: 11/04/2004 / O		

Please find below and/or attached an Office communication concerning this application or proceeding.

			4			
-7:		Application No.	Applicant(s)			
		09/870,144	SEVICK-MURACA ET AL.			
	Office Action Summary	Examiner	Art Unit			
		William Jung	3737			
Period fo	The MAILING DATE of this communication app	ears on the cover sheet with the	correspondence address			
A SH THE - Exte after - If the - If NC - Failu Any earn	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing end patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ti within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS fron cause the application to become ABANDON	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
·	Responsive to communication(s) filed on 12 Ja		•			
/	·—	action is non-final.				
3)						
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Disposit	ion of Claims					
4)⊠	Claim(s) <u>1-34</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>1-34</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/or	r election requirement.				
Applicati	ion Papers		•			
9)[	The specification is objected to by the Examine	r.				
10)	0)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	e Action or form PTO-152.			
Priority ι	under 35 U.S.C. § 119					
a)	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  Certified copies of the priority documents  Certified copies of the priority documents  Copies of the certified copies of the priority documents  application from the International Bureau	s have been received. s have been received in Applicati rity documents have been receiv u (PCT Rule 17.2(a)).	tion No red in this National Stage			
Attachmen  1) Notice 2) Notice 3) Infor	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	4)	y (PTO-413)			
-ape	er No(s)/Mail Date	o) 🗀 Oulei				

Application/Control Number: 09/870,144

Art Unit: 3737

### **DETAILED ACTION**

## Response to Arguments

1. Applicant's arguments with respect to claims 1-34 have been considered but are moot in view of the new ground(s) of rejection.

## Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

3. Claims 1-34 are rejected under 35 U.S.C. 102(e) as being anticipated by *Hochman et al* (US 5,699,798).

Hochman et al anticipate all claimed features in claims 1-34.

Claims 1, 8-11, 15-17, 19-23, and 28-34: Hochman et al discloses a method of introducing an exogenous fluorescent contrast agent into a tissue where the tissue multiply scattering light with a time-of-flight and the contrast agent having a fluorescent life time within a

factor of ten of the time-of-flight. The method further includes exposing the tissue to an excitation light with a varying intensity and detecting a light emission from the tissue in response to the light exposure and generating an image of the tissue my mapping variation of a level of a fluorescence characteristic of the tissue from the light emission in accordance with light scattering behavior of the tissue (col. 3, line 22 – col. 4, line 12; col. 5, lines 39-59; col. 9, lines 37-60).

Claims 2-7, 12-14, 18-22, and 24-29: Furthermore, Hochman et al disclose that the dye or fluorescent contrast agent has a specific lifetime (col. 16, lines 51-55). Although Hochman et al do not specifically lists the fluorescent lifetime in nanosecond scale, it is implied that the lifetime of the fluorescent agent is dependent on the dye characteristic combined with tissue, e.g. for malignant tumors, the fluorescent lifetime is longer. Therefore, the limitation on the lifetime of the contrast agent is a design choice.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William Jung, Ph.D. whose telephone number is 703-605-4364. The examiner can normally be reached on Mon-Fri 8:30 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/870,144

Art Unit: 3737

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

NO

October 21, 2004

BRIAN L. CASLER SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 3700